JP2023504286A - 薬物送達のためのデンドリマー組成物および方法 - Google Patents

薬物送達のためのデンドリマー組成物および方法 Download PDF

Info

Publication number
JP2023504286A
JP2023504286A JP2022534289A JP2022534289A JP2023504286A JP 2023504286 A JP2023504286 A JP 2023504286A JP 2022534289 A JP2022534289 A JP 2022534289A JP 2022534289 A JP2022534289 A JP 2022534289A JP 2023504286 A JP2023504286 A JP 2023504286A
Authority
JP
Japan
Prior art keywords
composition
dendrimer
inhibitor
tumor
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022534289A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023504286A5 (https=
Inventor
ジェフリー クリーランド，
リシ シャルマ，
ミンハオ ソン，
サンティアゴ アピアニ，
Original Assignee
アシュバッタ セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アシュバッタ セラピューティクス， インコーポレイテッド filed Critical アシュバッタ セラピューティクス， インコーポレイテッド
Publication of JP2023504286A publication Critical patent/JP2023504286A/ja
Publication of JP2023504286A5 publication Critical patent/JP2023504286A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2022534289A 2019-12-04 2020-12-04 薬物送達のためのデンドリマー組成物および方法 Pending JP2023504286A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962943705P 2019-12-04 2019-12-04
US62/943,705 2019-12-04
US202063108186P 2020-10-30 2020-10-30
US63/108,186 2020-10-30
PCT/US2020/063332 WO2021113651A2 (en) 2019-12-04 2020-12-04 Dendrimer compositions and methods for drug delivery

Publications (2)

Publication Number Publication Date
JP2023504286A true JP2023504286A (ja) 2023-02-02
JP2023504286A5 JP2023504286A5 (https=) 2023-12-13

Family

ID=74104190

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022534289A Pending JP2023504286A (ja) 2019-12-04 2020-12-04 薬物送達のためのデンドリマー組成物および方法

Country Status (9)

Country Link
US (3) US20210170040A1 (https=)
EP (1) EP4069307A2 (https=)
JP (1) JP2023504286A (https=)
CN (1) CN115103689A (https=)
AU (1) AU2020397063A1 (https=)
CA (1) CA3163886A1 (https=)
IL (1) IL293604A (https=)
PH (1) PH12022551368A1 (https=)
WO (1) WO2021113651A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7759322B2 (ja) 2019-12-04 2025-10-23 アシュバッタ セラピューティクス， インコーポレイテッド 眼に薬物送達するためのデンドリマー組成物および方法
PH12022552818A1 (en) 2020-04-24 2024-03-25 Ashvattha Therapeutics Inc Dendrimer compositions and methods for treatment of severe acute respiratory distress syndrome
US20230364244A1 (en) * 2020-07-17 2023-11-16 Ashvattha Therapeutics, Inc. Dendrimer compositions and methods for drug delivery to injured kidney
WO2022094327A1 (en) * 2020-10-30 2022-05-05 Ashvattha Therapeutics, Inc. Radiolabeled ether dendrimer conjugates for pet imaging and radiotherapy
US20240139107A1 (en) * 2021-03-08 2024-05-02 Transdermal Biotechnology, Inc. Dendrimer-n-acetyl-l-cysteine conjugates for treatment or prevention of aging skin or other indications
WO2022261504A1 (en) * 2021-06-10 2022-12-15 Ashvattha Therapeutics, Inc. Dendrimer conjugates and methods of use thereof
WO2023173124A1 (en) * 2022-03-10 2023-09-14 Cheng Kun Novel phosphoinositide 3-kinase (pi3k) inhibitor, compositions comprising the same, methods of making, and methods of treating a disease
WO2023183367A1 (en) * 2022-03-22 2023-09-28 Board Of Regents Of The University Of Nebraska Metformin nanoformulations and methods of use thereof
CN114796492B (zh) * 2022-05-12 2023-01-13 大连理工大学 一种超声驱动纳米声敏疫苗及其制备和应用
CN116196292B (zh) * 2023-02-16 2024-08-16 东华大学 一种靶向肽修饰的聚酰胺-胺树状大分子复合纳米材料及其制备方法
WO2025183982A1 (en) * 2024-02-28 2025-09-04 Washington State University Psma-targeted dendrimer nanoplatform for cancer detection and therapy
WO2025226820A1 (en) * 2024-04-23 2025-10-30 Ashvattha Therapeutics, Inc. Csf1r inhibitor dendrimer conjugates and uses thereof
CN118108799B (zh) * 2024-04-29 2024-07-12 内蒙古工业大学 基于DMXAA的含Se多肽药物及其制备方法和应用
WO2025259214A1 (en) 2024-06-14 2025-12-18 EGE Kimya San. ve Tic. A.S. Use of dendrimer compounds as anti-skinning agents
WO2025259215A1 (en) 2024-06-14 2025-12-18 EGE Kimya San. ve Tic. A.S. Use of dendrimer compounds as complexing ligands for metal activity enhancement
CN118846078A (zh) * 2024-07-02 2024-10-29 中国人民解放军空军军医大学 Ndrg2基因联合分子靶向抑制剂在制备肾细胞癌治疗药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017514814A (ja) * 2014-04-30 2017-06-08 ザ・ジョンズ・ホプキンス・ユニバーシティー デンドリマー組成物および眼の疾患の処置におけるその使用
JP2017537985A (ja) * 2014-12-15 2017-12-21 ザ ジョーンズ ホプキンズ ユニバーシティＴｈｅ Ｊｏｈｎｓ Ｈｏｐｋｉｎｓ Ｕｎｉｖｅｒｓｉｔｙ スニチニブ製剤及び眼の障害の治療におけるその使用に対する方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3856807A (en) 1972-03-13 1974-12-24 Upjohn Co L-({60 s,5s)-{60 -amino-3-chloro-2-isoxazoline-5-acetic acid
US3878047A (en) 1973-02-02 1975-04-15 Upjohn Co Process for production of AT-125
US5087639A (en) 1988-11-02 1992-02-11 The Upjohn Company Preventing CNS toxicity of acivicin when used with four large neutral amino acids
CA2940803A1 (en) * 2004-03-23 2005-10-27 Ascendis Pharma Gmbh Prodrug linker
PL2214646T3 (pl) * 2007-10-05 2021-12-20 Wayne State University Dendrymery do przedłużonego uwalniania związków
CA2767163A1 (en) 2009-06-15 2010-12-23 Wayne State University Dendrimer based nanodevices for therapeutic and imaging purposes
EP2552458A4 (en) 2010-03-31 2014-08-27 Univ Wayne State INJECTABLE DENDRIMER HYDROGEL NANOPARTICLES
US9198973B2 (en) * 2013-06-17 2015-12-01 Fundacion Fraunhofer Chile Research PAMAM, spacer molecule and cafestol polymers
EA036983B1 (ru) * 2014-05-21 2021-01-22 АйСиДи-ТЕРАПЬЮТИКС ГМБХ Терапевтические конъюгаты с сульфатированными дендримерами для внутриклеточного нацеливания
CN106659798A (zh) * 2014-08-13 2017-05-10 约翰霍普金斯大学 树枝状聚合物组合物和在治疗神经与cns病症中的用途
JP6342575B2 (ja) * 2014-08-13 2018-06-13 ザ・ジョンズ・ホプキンス・ユニバーシティー 脳腫瘍への選択的デンドリマー送達
KR101918346B1 (ko) * 2015-05-06 2018-11-13 경북대학교 산학협력단 난용성 활성물질의 수용성 덴드리머 복합체
CN108289872B (zh) * 2015-10-29 2021-04-02 约翰霍普金斯大学 树枝状聚合物组合物和其在坏死性小肠结肠炎和其它胃肠道病症治疗中的用途
US20190142953A1 (en) * 2016-05-10 2019-05-16 Massachusetts Institute Of Technology Dendrimer-Drug Conjugates, Hydrogel Compositions, and Methods
TWI773730B (zh) * 2017-02-22 2022-08-11 瑞典商阿斯特捷利康公司 治療性樹枝狀聚合物
WO2019071153A1 (en) * 2017-10-05 2019-04-11 Sony Corporation PROGRAMMABLE DENDRITIC MEDICINES
US11918657B2 (en) * 2017-11-10 2024-03-05 The Johns Hopkins University Dendrimer delivery system and methods of use thereof
US20210330600A1 (en) * 2018-12-21 2021-10-28 Tiba Biotech Llc Nanoparticle compositions for efficient nucleic acid delivery and methods of making and using the same
JP7759322B2 (ja) * 2019-12-04 2025-10-23 アシュバッタ セラピューティクス， インコーポレイテッド 眼に薬物送達するためのデンドリマー組成物および方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017514814A (ja) * 2014-04-30 2017-06-08 ザ・ジョンズ・ホプキンス・ユニバーシティー デンドリマー組成物および眼の疾患の処置におけるその使用
JP2017537985A (ja) * 2014-12-15 2017-12-21 ザ ジョーンズ ホプキンズ ユニバーシティＴｈｅ Ｊｏｈｎｓ Ｈｏｐｋｉｎｓ Ｕｎｉｖｅｒｓｉｔｙ スニチニブ製剤及び眼の障害の治療におけるその使用に対する方法

Also Published As

Publication number Publication date
US20210170040A1 (en) 2021-06-10
US20230226199A1 (en) 2023-07-20
PH12022551368A1 (en) 2023-05-08
EP4069307A2 (en) 2022-10-12
CA3163886A1 (en) 2021-06-10
AU2020397063A1 (en) 2022-07-07
US20230372499A1 (en) 2023-11-23
IL293604A (en) 2022-08-01
WO2021113651A3 (en) 2021-08-26
CN115103689A (zh) 2022-09-23
WO2021113651A2 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
JP2023504286A (ja) 薬物送達のためのデンドリマー組成物および方法
TWI756686B (zh) 細胞毒性劑經由支鏈連接子與細胞結合分子的偶聯物
Yu et al. Inhibiting metastasis and preventing tumor relapse by triggering host immunity with tumor-targeted photodynamic therapy using photosensitizer-loaded functional nanographenes
US11433136B2 (en) Polyacetal polymers, conjugates, particles and uses thereof
JP7719072B2 (ja) 三分岐ｎ－アセチルガラクトサミン修飾ヒドロキシルポリアミドアミンデンドリマーおよびその使用方法
CN113164589A (zh) 用于调节单核细胞和巨噬细胞发炎表型的组合物和方法以及其免疫疗法用途
BR112020010405A2 (pt) compostos conjugado conectado à cadeia lateral e de conexão de cadeia lateral, cadeias laterais q1 e q2, d (estrutura de tubulisina), w, l1, l2, v1 e v2, agente/molécula de ligação de célula, célula de tumor, composição farmacêutica, e, agentes quimioterapêutico e sinergísticos
ES2863369T7 (es) Terapias inmunoablativas
US20250049963A1 (en) Glycosylated dendrimers for targeted intracellular delivery
JP2022545636A (ja) 癌の免疫療法のための高性能ペプチド及び可変ナノ粒子
JP2021523151A (ja) 負の表面電荷を有するマイクロ粒子及びナノ粒子
US12303724B2 (en) Non-adult human dosing of anti-CD30 antibody-drug conjugates for treatment of hematological or lymphoid cancer
EP4301340A1 (en) Micelle releasing thermosensitive hydrogels as a therapeutic delivery system
JP2023549464A (ja) Ｂ細胞免疫寛容の誘導及びｍＩｇＭ陽性発現Ｂ細胞リンパ腫の標的化における葉酸及び葉酸修飾の使用
JP2025518126A (ja) がんの治療のための同種異系低免疫生体模倣型ナノ小胞
US20230381349A1 (en) Methods and compositions for imaging and treating cancer
HK40081468A (en) Dendrimer compositions and methods for drug delivery
US20210322508A1 (en) Peptides and compositions for targeted treatment and imaging
Need et al. Positron Emission Tomography of CD47/SIRPα Axis and Image-Informed Therapeutic Design
TW202608449A (zh) 替拉紮明（ｔｉｒａｐａｚａｍｉｎｅ）組合物及方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241218

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250617

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250926

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260325